Seth E Karol
Overview
Explore the profile of Seth E Karol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Place A, Karol S, Forlenza C, Cooper T, Fraser C, Cario G, et al.
Pediatr Blood Cancer
. 2025 Mar;
:e31630.
PMID: 40062648
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and although many patients respond to induction therapy, those who relapse or have refractory disease face a poor prognosis....
2.
3.
Neel M, Murphy S, Kaste S, Defeo B, Karol S, Klug P, et al.
J Pediatr Orthop
. 2025 Mar;
45(4):e358-e365.
PMID: 40038905
Background: Despite success in treating childhood acute lymphoblastic leukemia and lymphoma (ALL), modern multiagent chemotherapy regimens containing high-dose corticosteroids can result in osteonecrosis afflicting survivors, frequently involving the knee. Thus,...
4.
Panetta J, Ashcraft E, Jeha S, Pui C, Inaba H, Karol S, et al.
Haematologica
. 2025 Feb;
PMID: 39945009
Not available.
5.
Matherne M, Panetta J, Hopp J, Inaba H, Pui C, Karol S, et al.
Blood Adv
. 2025 Feb;
PMID: 39903102
No abstract available.
6.
Li Z, Zhao H, Yang W, Maillard M, Yoshimura S, Hsiao Y, et al.
Nat Commun
. 2025 Jan;
16(1):1153.
PMID: 39880832
ETV6::RUNX1 is the most common fusion gene in childhood acute lymphoblastic leukemia (ALL) associated with favorable prognosis, but the optimal therapy for this subtype remains unclear. Profiling the genomic and...
7.
Umeda M, Liu Y, Karol S, Klco J
Haematologica
. 2025 Jan;
PMID: 39781610
The prognosis of pediatric acute myeloid leukemia (AML) remains poor compared with pediatric acute lymphoblastic leukemia (ALL); accurate diagnosis and treatment strategies based on the genomic background are strongly needed....
8.
Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic Ethnicity
Maillard M, Nguyen J, Yang W, Hoshitsuki K, Relling M, Caudle K, et al.
Clin Pharmacol Ther
. 2024 Dec;
117(3):724-731.
PMID: 39688234
Nudix hydrolase 15 (NUDT15) deficiency is strongly associated with thiopurine-induced myelosuppression. Currently, testing for NUDT15 deficiency is based on the genotyping of the most frequent and clinically characterized no-function variants,...
9.
Mostafa A, Abramson Z, Ghbrial M, Biswas S, Chan S, Darji H, et al.
Cancer Imaging
. 2024 Oct;
24(1):138.
PMID: 39402660
No abstract available.
10.
Badawi M, Gopalakrishnan S, Engelhardt B, Palenski T, Karol S, Rubnitz J, et al.
Clin Ther
. 2024 Oct;
46(10):759-767.
PMID: 39368878
Purpose: This work aimed to characterize the pharmacokinetics and exposure-response relationships of venetoclax in pediatric patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) to identify venetoclax doses to...